Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
复制标题
Ano1/TMEM16A 过度表达与 PR 阳性或 HER2 阴性乳腺癌患者接受他莫昔芬治疗后的良好预后相关
DOI：
10.1371/journal.pone.0126128
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Wei M
中科院分区：
文献类型：
--
作者：
Wu H;Guan S;Sun M;Yu Z;Zhao L;He M;Zhao H;Yao W;Wang E;Jin F;Xiao Q;Wei M
钙激活氯通道Ano1(TMEM16A)在许多肿瘤中高表达。虽然由于11q13扩增，在乳腺癌中发现了Ano1的过表达，但目前还不清楚在乳腺癌体内发生过程中是否有信号通路参与了Ano1的过表达。已知雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)与乳腺癌的进展有关。目前尚不清楚Ano1是否与不同ER、PR和HER2状态的乳腺癌患者的临床预后有关。本研究采用免疫组织化学方法检测了431例浸润性导管癌和46例纤维腺瘤组织中Ano1的表达，并分析了不同ER、PR和HER2状态的乳腺癌患者Ano1表达与临床特征和预后的关系。与纤维腺瘤相比，Ano1在乳腺癌中高表达。临床分期较低(I期或II期)或三阴性状态的乳腺癌与ANO1显著相关。最重要的是，在PR阳性或HER2阴性的患者以及接受三苯氧胺治疗的患者中，Ano1的过度表达与良好的预后相关。多变量COX回归分析显示，在PR阳性或HER2阴性的患者中，Ano1的过度表达是延长总生存期的预后因素，在他莫昔芬治疗后的患者中，Ano1的过度表达是总生存期延长的预测因素。我们的研究结果表明，在PR阳性或HER2阴性的患者接受三苯氧胺治疗后，Ano1可能是一个潜在的预后良好的标志物。PR和HER2状态定义了乳腺癌的一种亚型，在这种亚型中，Ano1的过度表达与他莫昔芬治疗后的良好预后有关。
The calcium-activated chloride channel Ano1 (TMEM16A) is overexpressed in many tumors. Although Ano1 overexpression is found in breast cancer due to 11q13 amplification, it remains unclear whether signaling pathways are involved in Ano1 overexpression during breast cancer tumorigenesis in vivo. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have been known to contribute to breast cancer progression. It is unclear whether Ano1 is associated with clinical outcomes in breast cancer patients with different ER, PR and HER2 status. In the present study, we investigated the Ano1 expression in 431 patients with invasive ductal breast carcinoma and 46 patients with fibroadenoma, using immunohistochemistry, and analyzed the association between Ano1 expression and clinical characteristics and outcomes of breast cancer patients with different ER, PR, and HER2 status. Ano1 was overexpressed in breast cancer compared with fibroadenoma. Ano1 was significantly more associated with breast cancer with the lower clinical stage (stage I or II), or triple-negative status. Mostly importantly, Ano1 overexpression was associated with good prognosis in patients with the PR-positive or HER2-negative status, and in patients following tamoxifen treatment. Multivariate Cox regression analysis showed that Ano1 overexpression was a prognostic factor for longer overall survival in PR-positive or HER2-negative patients, and a predictive factor for longer overall survival in patients following tamoxifen treatment. Our findings suggest that Ano1 may be a potential marker for good prognosis in PR-positive or HER2-negative patients following tamoxifen treatment. The PR and HER2 status defines a subtype of breast cancer in which Ano1 overexpression is associated with good prognosis following tamoxifen treatment.
登录
查看更多内容
影响因子：
3.9
作者：
Lambrechts, Diether;Truong, Therese;Justenhoven, Christina;Humphreys, Manjeet K.;Wang, Jean;Hopper, John L.;Dite, Gillian S.;Apicella, Carmel;Southey, Melissa C.;Schmidt, Marjanka K.;Broeks, Annegien;Cornelissen, Sten;van Hien, Richard;Sawyer, Elinor;Tomlinson, Ian;Kerin, Michael;Miller, Nicola;Milne, Roger L.;Pilar Zamora, M.;Arias Perez, Jose Ignacio;Benitez, Javier;Hamann, Ute;Ko, Yon-Dschun;Bruening, Thomas;Chang-Claude, Jenny;Eilber, Ursel;Hein, Rebecca;Nickels, Stefan;Flesch-Janys, Dieter;Wang-Gohrke, Shan;John, Esther M.;Miron, Alexander;Winqvist, Robert;Pylkas, Katri;Jukkola-Vuorinen, Arja;Grip, Mervi;Chenevix-Trench, Georgia;Beesley, Jonathan;Chen, Xiaoqing;Menegaux, Florence;Cordina-Duverger, Emilie;Shen, Chen-Yang;Yu, Jyh-Cherng;Wu, Pei-Ei;Hou, Ming-Feng;Andrulis, Irene L.;Selander, Teresa;Glendon, Gord;Mulligan, Anna Marie;Anton-Culver, Hoda;Ziogas, Argyrios;Muir, Kenneth R.;Lophatananon, Artitaya;Rattanamongkongul, Suthee;Puttawibul, Puttisak;Jones, Michael;Orr, Nicholas;Ashworth, Alan;Swerdlow, Anthony;Severi, Gianluca;Baglietto, Laura;Giles, Graham;Southey, Melissa;Marme, Federik;Schneeweiss, Andreas;Sohn, Christof;Burwinkel, Barbara;Yesilyurt, Betul T.;Neven, Patrick;Paridaens, Robert;Wildiers, Hans;Brenner, Hermann;Mueller, Heiko;Arndt, Volker;Stegmaier, Christa;Meindl, Alfons;Schott, Sarah;Bartram, Claus R.;Schmutzler, Rita K.;Cox, Angela;Brock, Ian W.;Elliott, Graeme;Cross, Simon S.;Fasching, Peter A.;Schulz-Wendtland, Ruediger;Ekici, Arif B.;Beckmann, Matthias W.;Fletcher, Olivia;Johnson, Nichola;Silva, Isabel dos Santos;Peto, Julian;Nevanlinna, Heli;Muranen, Taru A.;Aittomaki, Kristiina;Blomqvist, Carl;Doerk, Thilo;Schuermann, Peter;Bremer, Michael;Hillemanns, Peter;Bogdanova, Natalia V.;Antonenkova, Natalia N.;Rogov, Yuri I.;Karstens, Johann H.;Khusnutdinova, Elza;Bermisheva, Marina;Prokofieva, Darya;Gancev, Shamil;Jakubowska, Anna;Lubinski, Jan;Jaworska, Katarzyna;Durda, Katarzyna;Nordestgaard, Borge G.;Bojesen, Stig E.;Lanng, Charlotte;Mannermaa, Arto;Kataja, Vesa;Kosma, Veli-Matti;Hartikainen, Jaana M.;Radice, Paolo;Peterlongo, Paolo;Manoukian, Siranoush;Bernard, Loris;Couch, Fergus J.;Olson, Janet E.;Wang, Xianshu;Fredericksen, Zachary;Alnaes, Grethe Grenaker;Kristensen, Vessela;Borresen-Dale, Anne-Lise;Devilee, Peter;Tollenaar, Robert A. E. M.;Seynaeve, Caroline M.;Hooning, Maartje J.;Garcia-Closas, Montserrat;Chanock, Stephen J.;Lissowska, Jolanta;Sherman, Mark E.;Hall, Per;Liu, Jianjun;Czene, Kamila;Kang, Daehee;Yoo, Keun-Young;Noh, Dong-Young;Lindblom, Annika;Margolin, Sara;Dunning, Alison M.;Pharoah, Paul D. P.;Easton, Douglas F.;Guenel, Pascal;Brauch, Hiltrud
通讯作者：
Brauch, Hiltrud
影响因子：
11.2
作者：
Bicaku, Elona;Marchion, Douglas C.;Munster, Pamela N.
通讯作者：
Munster, Pamela N.
影响因子：
45.3
作者：
Coates, Alan S.;Keshaviah, Aparna;Goldhirsch, Aron
通讯作者：
Goldhirsch, Aron
影响因子：
6.4
作者：
Akpalo, Hana;Lange, Claudia;Zustin, Jozef
通讯作者：
Zustin, Jozef
DOI：
10.1073/pnas.1200174109
发表时间：
2012-06-26
影响因子：
11.1
作者：
Perez-Cornejo, Patricia;Gokhale, Avanti;Faundez, Victor
通讯作者：
Faundez, Victor